Breakthrough invasive fungal infections: Who is at risk?

Jeffrey D. Jenks; Oliver A. Cornely; Sharon C.A. Chen; George R. Thompson; Martin Hoenigl

doi:10.1111/myc.13148

Breakthrough invasive fungal infections: Who is at risk?

Jeffrey D. Jenks, Oliver A. Cornely, Sharon C.A. Chen, George R. Thompson, Martin Hoenigl

Division of Hospital Medicine

Research output: Contribution to journal › Review article › peer-review

55 Scopus citations

Abstract

The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs. Although this strategy has resulted in an overall reduction in IFIs, a subset of patients develop breakthrough IFIs with substantial morbidity and mortality in this population. Here, we review the most significant risk factors for breakthrough IFIs in haematology patients, solid organ transplant recipients, and patients in the intensive care unit, focusing particularly on host factors, and highlight areas that require future investigation.

Original language	English (US)
Pages (from-to)	1021-1032
Number of pages	12
Journal	Mycoses
Volume	63
Issue number	10
DOIs	https://doi.org/10.1111/myc.13148
State	Published - Oct 1 2020

Keywords

breakthrough fungal infections
fungal infections
risk factors

ASJC Scopus subject areas

Dermatology
Infectious Diseases

Access to Document

10.1111/myc.13148

Cite this

@article{fbc51841f7ec457e80501ef9142e6f82,

title = "Breakthrough invasive fungal infections: Who is at risk?",

abstract = "The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs. Although this strategy has resulted in an overall reduction in IFIs, a subset of patients develop breakthrough IFIs with substantial morbidity and mortality in this population. Here, we review the most significant risk factors for breakthrough IFIs in haematology patients, solid organ transplant recipients, and patients in the intensive care unit, focusing particularly on host factors, and highlight areas that require future investigation.",

keywords = "breakthrough fungal infections, fungal infections, risk factors",

author = "Jenks, {Jeffrey D.} and Cornely, {Oliver A.} and Chen, {Sharon C.A.} and Thompson, {George R.} and Martin Hoenigl",

note = "Funding Information: This work was supported using funds from the Oesterreichische Nationalbank (Anniversary Fund, project number 15346) and has been partially supported by grants from the National Institutes of Health (MH 113477, AI106039, AI036214 and MH062512). The funders had no role in the study design, data collection, analysis, interpretation and decision to publish, in the writing of the manuscript, or in the decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2020 Wiley-VCH GmbH",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/myc.13148",

language = "English (US)",

volume = "63",

pages = "1021--1032",

journal = "Mykosen",

issn = "0933-7407",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - Breakthrough invasive fungal infections

T2 - Who is at risk?

AU - Jenks, Jeffrey D.

AU - Cornely, Oliver A.

AU - Chen, Sharon C.A.

AU - Thompson, George R.

AU - Hoenigl, Martin

N1 - Funding Information: This work was supported using funds from the Oesterreichische Nationalbank (Anniversary Fund, project number 15346) and has been partially supported by grants from the National Institutes of Health (MH 113477, AI106039, AI036214 and MH062512). The funders had no role in the study design, data collection, analysis, interpretation and decision to publish, in the writing of the manuscript, or in the decision to submit the manuscript for publication. Publisher Copyright: © 2020 Wiley-VCH GmbH

PY - 2020/10/1

Y1 - 2020/10/1

N2 - The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs. Although this strategy has resulted in an overall reduction in IFIs, a subset of patients develop breakthrough IFIs with substantial morbidity and mortality in this population. Here, we review the most significant risk factors for breakthrough IFIs in haematology patients, solid organ transplant recipients, and patients in the intensive care unit, focusing particularly on host factors, and highlight areas that require future investigation.

AB - The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs. Although this strategy has resulted in an overall reduction in IFIs, a subset of patients develop breakthrough IFIs with substantial morbidity and mortality in this population. Here, we review the most significant risk factors for breakthrough IFIs in haematology patients, solid organ transplant recipients, and patients in the intensive care unit, focusing particularly on host factors, and highlight areas that require future investigation.

KW - breakthrough fungal infections

KW - fungal infections

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=85090167821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090167821&partnerID=8YFLogxK

U2 - 10.1111/myc.13148

DO - 10.1111/myc.13148

M3 - Review article

C2 - 32744334

AN - SCOPUS:85090167821

SN - 0933-7407

VL - 63

SP - 1021

EP - 1032

JO - Mykosen

JF - Mykosen

IS - 10

ER -

Breakthrough invasive fungal infections: Who is at risk?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this